.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,440,458

« Back to Dashboard

Claims for Patent: 6,440,458

Title: Sustained release preparations
Abstract:Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.
Inventor(s): Yamashita; Kazunari (Muko, JP), Hashimoto; Eiji (Hashimoto, JP), Nomura; Yukihiro (Osaka, JP), Shimojo; Fumio (Kawanishi, JP), Tamura; Shigeki (Osaka, JP), Hirose; Takeo (Kyoto, JP), Ueda; Satoshi (Kawanishi, JP), Saitoh; Takashi (Osaka, JP), Ibuki; Rinta (Kyoto, JP), Ideno; Toshio (Takatsuki, JP)
Assignee: Fujisawa Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:09/403,787
Patent Claims: 1. A sustained-release formulation comprising tacrolimus or its hydrate wherein the time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours, as measured according to the Japanese Pharmacopoeia, the 13-th edition, Dissolution Test, No. 2 (Puddle method, 50 rpm) using a test solution which is an aqueous 0.005% hydroxypropyl cellulose solution adjusted to pH 4.5, which comprises a solid dispersion composition, wherein tacrolimus or its hydrate is present as an amorphous state in water-insoluble polymer.

2. The sustained-release formulation in claim 1, wherein the weight ratio of tacrolimus to water-insoluble polymer is 1 to 0.1-5.

3. The sustained-release formulation in claim 1, wherein the water-insoluble polymer is ethylcellulose or methacrylate copolymers.

4. The sustained-release formulation in claim 1, wherein the solid dispersion composition is characterized by (1) lactose or calcium hydrogen phosphate is contained as an excipient and/or lubricant, and (2) the particle size of the said solid dispersion composition is equal to or smaller than 350 .mu.m.

5. The sustained-release formulation in claim 4, wherein the solid dispersion composition is characterized by (1) tacrolimus or its hydrate is present as an amorphous state in ethylcellulose, (2) lactose is contained as an excipient, and (3) the particle size of the said solid dispersion composition is equal to or smaller than 250 .mu.m.

6. The sustained-release formulation in claim 1, wherein water-soluble polymer is mixed with the water-insoluble polymer.

7. The sustained-release formulation in claim 6, wherein the water-soluble polymer is hydroxypropylmethyl cellulose.

8. The sustained-release formulation in claim 7, wherein the weight ratio of tacrolimus to hydroxypropylmethyl cellulose is 1 to 0.2-0.4.

9. The sustained-release formulation in claim 6, wherein the solid dispersion composition is characterized by (1) tacrolimus or its hydrate is present as an amorphous state in a mixture of ethylcellulose and hydroxypropylmethyl cellulose, (2) lactose is contained as an excipient, (3) the particle size of the said solid dispersion composition is equal to or smaller than 250 .mu.m.

10. The sustained-release formulation in claim 1, in which the time (T63.2%) is 1.3 to 8.2 hours.

11. The sustained-release formulation in claim 1, in which the time (T63.2%) is 2 to 5 hours.

12. The sustained-release formulation in claim 1, which is in a form of powder, fine powder, granule, tablet or capsule.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc